Vall d'Hebron
Search

Home > Research Team > Javier Cortés

Javier Cortés

Javier Cortés

Current positions

  • Deputy Director of the Breast Cancer Program
  • Head of the Melanoma Program
  • Specialist physician at the Oncology Department of Vall d’Hebron University Hospital
  • Tutor of residents in Medical Oncology of Vall d’Hebron Hospital
  • Member of the Board of Directors and Scientific Committee of the SOLTI Cooperative Group
  • Member of the Scientific Committee of the International Congress on Anti-Cancer Treatment (ICACT)

Academic Qualifications

  • Degree in Medicine and Surgery, 1996
  • Doctorate in Medicine and Surgery from the University of Navarra, 2002

Areas of Research

  • New microtubules in breast cancer
  • New forms and contents in HER2+ breast cancer
  • Integration of antiangiogenic agents in current breast cancer treatment
  • New targeted agents in breast cancer

Prizes and Scholarships

  • Scholarship from ASCO, AACR and from EORTC

Most relevant scientific publications

  • Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010 Mar; 28(7): 1131-7
  • Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010 Mar; 28(7): 1138-44
  • Ciruelos EM, Cortes J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Baselga J. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Ann. Oncol. 2010 Jul; 21(7): 1442-7
  • Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010 Jul; 28(20): 3239-47
  • Leyland-Jones B, Colomer R, Trudeau ME, Wardley A, Latreille J, Cameron D, Cubedo R, Al-Sakaff N, Feyereislova A, Catalani O, Fukushima Y, Brewster M, Cortes J. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J. Clin. Oncol. 2010 Feb; 28(6): 960-6
  • Cortes J, Baselga J. How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. J. Clin. Oncol. 2009 Nov; 27(33): 5492-4
  • Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodríguez CA, Trigo JM, Vazquez J, Regueiro P, Dorado JF, Baselga J. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin. Cancer Res. 2009 Jan; 15(1): 307-14
  • Martín M, González Palacios F, Cortes J, de la Haba J, Schneider J. Prognostic and predictive factors and genetic analysis of early breast cancer. Clin Transl Oncol 2009 Oct; 11(10): 634-42
  • Cortes J, Saura C, Atzori F. Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA 2009 Apr; 301(14): 1434-5; author reply 1435-6

All publications